Johnson & Johnson (JNJ), AstraZeneca plc (ADR) (AZN), The Procter & Gamble Company (PG): The Priceless Health Business Every Investor Overlooks

Page 1 of 2

Investors know Johnson & Johnson (NYSE:JNJ) for many things.

It’s arguably health care’s biggest name. The company’s pharmaceutical segment boasts billions of dollars in sales annually from its largest drug, immunology star Remicade, alone. It has a number of up-and-coming drugs ready to fuel the company’s future, and the firm’s orthopedics device division isn’t looking too bad recently, either, with the acquisition of medical device producer Synthes last year.

Yet many investors often forget about Johnson & Johnson (NYSE:JNJ)’s powerhouse consumer health business. It’s a business that demands your attention, however: With the volatile nature of health care today, strong consumer sales just might be Johnson & Johnson’s reliable foundation.

Johnson & Johnson (JNJ)

Grit, not glamour

Compared to J&J’s two other major businesses, its consumer health segment might not seem like much. It only posted sales of around $7.3 billion over the first half of the year. That’s a sizable sum to be sure, but it was only just over half of what the company’s medical device business sold in that same time span.

Compared to both devices and pharmaceuticals, consumer products also grew slowly. Sales for the segment climbed only 1.6% year-over-year over 2013′s first six months, far below the 9.9% and 11% from medical devices and pharmaceuticals, respectively.

So, why is this segment important to Johnson & Johnson (NYSE:JNJ) and its investors? Take a look inside its medical device and pharmaceuticals sales, and you’ll see that not every product or drug is hitting high marks for growth. Generic drug competition has torn down top neuroscience drug Concerta’s sales by more than 16% in the year’s first half.

While many of J&J’s drugs are showing strong growth, a quick look around the company’s big pharma rivals shows just how hard the patent cliff has hammered firms’ sales. AstraZeneca plc (ADR) (NYSE:AZN), one of big pharma’s top companies, saw sales decline by more than 15% last year with patent expirations hammering both the company’s top and bottom lines. As more drugs fall off patent in the near future, AstraZeneca plc (ADR) (NYSE:AZN)’s outlook remains murky – and its stock’s in a state of flux. While big pharma can mean big profits, the industry’s boom-or-bust nature can lead to serious investor disappointment.

Volatility doesn’t end with pharmaceuticals, either. J&J’s medical device segment might have grown strongly, but without its Synthes acquisition, the division’s performance so far this year hasn’t been quite as illustrious as a first glance might have suggested. Three of the division’s top five specialties by sales saw revenue fall over the year’s first half, part of a slowdown that’s affected many of the device industry’s leaders.

Adding stable growth

Up-and-down sales are the nature of health care, but that’s the beauty of Johnson & Johnson (NYSE:JNJ)’s consumer segment: It’s the cash cow that investors can count on. While growth may be elusive, this segment — accounting for more than 20% of the company’s overall revenue — is a reliable, if not glamorous, revenue producer.

It’s a trend symptomatic to the consumer health industry: Rival The Procter & Gamble Company (NYSE:PG)‘s health care division, a consumer-focused business, has posted 3% sales growth in each of the last three years, emerging as the conglomerate’s most reliable business in a time when other, higher-selling segments have seen revenue fall recently.

Consumer sales aren’t geographically exclusive, either: Johnson & Johnson (NYSE:JNJ)’s division posted similar growth in both the U.S. and internationally over the first six months of the year. This business likely won’t become an emerging market superstar, but as middle classes develop in growing economies such as India and Latin America, Johnson & Johnson is well-positioned to take advantage of basic health needs of consumers in such developing nations.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

5 Best States for Golf Adventures

Top 15 Places To Visit Before You Die

10 Most Expensive Smartphones in the World

10 States with Lowest Physician Density

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!